The University of Hong Kong
Hong Kong
NCT Number: NCT07345832
Sarcopenia prevention and management are highly prioritised goals in the Healthy Ageing agenda. The study aims to: 1) evaluate the effects of the digital-enhanced, volunteer-engaged collaborative care pathway to improve sarcopenia, reduce fall risk, and increase health-related quality of life (HRQL) among community-dwelling older adults with risk of, or diagnosed with, sarcopenia; 2) evaluate whether the volunteers who received health coach capacity training and supported the intervention experienced health benefits across time; 3) explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; 4) evaluate the intervention implementation process and effects from the perspectives of social care workers.
Trial opening soon.
Get Notified60 year and older
All sexes
Interventional
Not applicable
Hong Kong
Population ageing is accelerating worldwide, and the widening gap between life expectancy and healthy life expectancy is increasingly driven by late-life declines in physical function and mobility. Sarcopenia-an age-related, progressive syndrome characterised by reduced skeletal muscle strength and mass/quality with impaired physical performance-has become a key modifiable determinant of frailty, falls, disability, hospitalisation, and mortality among community-dwelling older adults. Using the Asian Working Group for Sarcopenia (AWGS) criteria, a systematic review and meta-analysis of studies in China reported a pooled prevalence of 12.9% among community-dwelling older adults. In Hong Kong, approximately 9% of adults aged 65 and above are diagnosed with sarcopenia, indicating a substantial community burden. Beyond functional loss, sarcopenia is associated with increased healthcare utilisation and costs, evidence suggests higher risks of hospital admission and longer length of stay among older adults with sarcopenia, contributing to considerable economic impact.
Contemporary consensus definitions (e.g., EWGSOP2 and AWGS) identify low muscle strength as the central feature, with muscle quantity/quality and physical performance used to confirm diagnosis and grade severity, which aligns management with interventions targeting strength, function, and nutritional status. Accordingly, guideline-based care emphasizes two key modalities: optimizing nutrition-particularly adequate protein intake to support muscle protein synthesis and, where indicated, correcting vitamin D deficiency-and implementing exercise programs centered on progressive resistance training, often complemented by functional and balance components to improve mobility and reduce falls risk. Evidence further suggests that combined exercise and nutritional strategies can outperform single-modality approaches for improving outcomes relevant to sarcopenia, including strength and physical performance.
Despite substantial evidence supporting lifestyle interventions, particularly exercise and nutritional optimization-for improving sarcopenia-related outcomes, these benefits are often time-limited in practice. When structured program support ends, the effective intervention "dose" commonly declines (e.g., reduced training frequency/intensity and weaker adherence to dietary targets), and improvements in strength, function, and overall physical performance may attenuate accordingly. This pattern is consistent with real-world evidence indicating that sustained benefits depend heavily on continued participation and adherence, with lower adherence associated with smaller functional gains than those observed under supervised or trial conditions. Therefore, for a progressive and chronic condition such as sarcopenia, the key challenge is not only initiating behavior change but ensuring that exercise and dietary practices are maintained and embedded into daily routines so that benefits can persist.
The above evidence underscores a key gap in sarcopenia management: many interventions and service models have limited capacity to sustain lifestyle behavioural changes over time. Maintenance requires that evidence-based recommendations be translated into routinised daily practices, supported by (i) person-centred assessment and tailoring, (ii) empowerment and goal-oriented self-management, and (iii) ongoing social reinforcement (peer/volunteer support) with timely follow-up. The WHO Integrated Care for Older People (ICOPE) framework provides a pragmatic structure to operationalise these requirements through intrinsic capacity assessment, personalised care planning, and continued community follow-up.
To address the above gaps, the VELO-S project proposes a 12-week, volunteer-engaged lifestyle optimisation programme grounded in WHO ICOPE and delivered through an ICOPE-based critical pathway for nutrition and exercise. VELO-S is enabled by a digital platform that contains an exhaustive checklist of person-centred risk factors and corresponding, precise lifestyle activity recommendations for each care pathway (nutrition and physical activity). After baseline screening, trained social care workers conduct care mapping to identify each participant's key barriers and preferences, select relevant risk factors within the platform, and generate a tailored set of recommended lifestyle actions. A simple personalised report summarising risk factors and agreed actions can then be produced (electronic or hard copy) for participants and the matched health coach, supporting shared understanding, goal-oriented follow-up, and iterative adjustment. In parallel, VELO-S incorporates goal-oriented empowerment and volunteer-enhanced interactive lifestyle empowerment workshops to strengthen motivation, social support, and practical capability for maintaining nutritional and activity changes, thereby targeting the sustainability mechanisms required to deter sarcopenia progression in community-dwelling older adults.
This overall study aims to evaluate the effects and implementation of VELO-S among community-dwelling older adults with pseudo-sarcopenia or sarcopenia.
The objectives of this study are to (1) examine the effectiveness of a 12-week VELO-S intervention compared to an attention control in improving appendicular skeletal muscle mass, handgrip strength, physical mobility function, risk of sarcopenia, frailty, nutrition, physical activity, and health-related quality of life among community-dwelling older adults with sarcopenia risk or sarcopenia at 12 weeks post-intervention and 24 weeks follow-up; (2) to examine changes in health-related quality of life and mental health among volunteers who participated in the health coach capacity training at 12 weeks post-intervention delivery and 24 weeks follow-up, compared to baseline; (3) to explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; (4) to explore the perspectives of social care workers on their experience on intervention effects and implementation process.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A series of interactive lifestyle empowerment workshops will be conducted at community centres to translate the care plan into sustainable behavioural changes. In addition to one session for individualised care planning, five 90-minute, bi-weekly, in-person, volunteer-enhanced interactive workshops led by nurses will be delivered to equip older adults with knowledge and practical skills to manage sarcopenia. Before interactive workshops, a brief orientation and strategic planning session will focus on the health coach's role, introduce participants to them, and pair each participant with a coach. Participants will be assisted by a corresponding health coach throughout the 12-week intervention workshop.
The attention control group receives six session meeting covering topics unrelated to sarcopenia, it will be delivered in a small-group with comparable duration and frequency of contact and engagement to those in the intervention group
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Appendicular skeletal muscle mass index (ASMI) measured by Bioelectrical impedance analysis (BIA)
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Handgrip strength will be measured by a hydraulic hand dynamometer from dominant hand, taking the highest value among 3 measurements. Low muscle strength is defined if male <28kg, and femal <18kg.
Time frame: baseline (T0), 3 months (T1), and 3 months (T2)
Physical function will be measured by the Short Physical Performance Battery (SPPB), which combines balance test, gait velocity and chair stand. SPPB score ranges from 0-12, higher score better physical performance. Low physical function is defined by SPPB score ≤9.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Sarcopenia and calf circumference scale (SARC-CalF) includes 5 items (strength, assistance with walking, rising from a chair, climbing stairs, Falls, calf circumference). The score ranges from 0 to 20 points, with a score ≥ 11 points suggestive of sarcopenia.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
The Edmonton Frail Scale (EFS) is scored from 0 to 17, with higher scores indicating greater frailty. An EFS score ≥ 8 is generally used as the cutoff for frailty. Scores 6-7 flag patients who are at risk.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Measured by the Timed Up and Go Test in unit of second. A shorter completion time indicates better mobility and balance.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Measured by the Mini Nutritional Assessment (scores range from 0 to 30), with a lower score indicating a higher risk of malnutrition.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Measured by International Physical Activity Questionnaire is a self-report measure of physical activity. Frenquency and time spent on walking, moderate and vigorous physical activity will be reported. More time spent on physical actiivty indicating a higher physical activity level.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Assess the health-related quality of life to generate the utility score for cost-effective analysis. Including the status on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a 5-level response set, with "unable to" levels mean a worse situation.
Time frame: Baseline (T0), 3 months (T1), and 6 months (T2)
Assess the health-related quality of lifeby a 0-100 scores Visual Analog Scale to measure perceived health, higher scores mean a better outcome.
Time frame: Baseline (T0)
Assess the comprehensive lipid panel including triglyceride, total cholesterol, high-density lipoprotein and low density lipoprotein through capillary blood samples collected via fingertip puncture
Time frame: Baseline (T0)
Assess the fasting glucose through capillary blood samples collected via fingertip puncture
Contact information is provided by the study sponsor or research team.
The University of Hong Kong
Other
The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07710456
Atrophy, Body Weight
View Trial DetailsNCT07275996
Aging, Atrophy
Burgos, Castille and León, Spain
View Trial DetailsNCT07561138
Atrophy, Behavior
Athens, Attica, Greece
View Trial DetailsNCT06988176
Atrophy, Elderly (People Aged 65 or More)
Chapel Hill, North Carolina, United States
View Trial Details